3071 A phase II study of carboplatin (Cb), pemetrexed (PEM), and bevacizumab (Bev) followed by Bev and erlotinib (Erl) maintenance for non-squamous non-small cell lung cancer (NS-NSCLC) with wild-type (WT) EGFR. (September 2015) - Takashina, T.; Asahina, H.; Yamada, N.; Harada, M.; Nakano, K.; Yokouchi, H.; Kanazawa, K.; Takamura, K.; Ogi, T.; Harada, T.; Honjo, O.; Morikawa, N.; et al.